Book an Appointment

Oral Peanut Immunotherapy is One Step Closer to FDA Approval

Oral Peanut Immunotherapy is One Step Closer to FDA Approval
Oral Peanut Immunotherapy is One Step Closer to FDA Approval

A recent vote by an FDA advisory committee is recommending eventual FDA approval of Palforzia, a novel therapy that may be indicated for patients between 4 and 17 years with peanut allergies.

Previous studies have shown that 67.2% of patients between ages 4 and 17 years old were able to ingest a dose of 600 mg or more of peanut protein after receiving Palforzia compared to 4% of patients who received the placebo. This effect was not seen in patients 18 years or older.

This therapy is not a cure for peanut allergy but may prevent severe allergic reactions from accidental ingestion of peanuts.

An anticipated date for final approval by the FDA may be in late January 2020.